Key facts
- Notable investors include Kumamoto University, SIIF Impact Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for C-HAS
- ·The full record, as it builds
Funding rounds
No funding rounds for C-HAS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About C-HAS
Developer of ingredient evaluation and product creation technologies designed for health and wellness applications. The company's platform utilizes a proprietary analysis system based on Caenorhabditis elegans (nematode) models to assess the health effects of natural ingredients, enabling researchers and product developers in the nutraceutical and cosmetics industries to identify, verify, and optimize bioactive compounds while reducing reliance on traditional animal testing.
- Sector
- Healthcare
- HQ
- Kumamoto, Japan
- Founded
- 2019
- Employees
- 10
- Website
- c-hasplus.co.jp/
- Ownership
- Privately Held (backing)
C-HAS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in C-HAS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on C-HAS in its N-PORT filings yet. We sweep new filings monthly.